Drug intelligence / Profile preview

JNJ-56136379 + entecavir

Development stage: Unknown
Lead developer: Johnson & Johnson
Modality: Small Molecules
Administration: Oral

Overview

JNJ-56136379 + entecavir is an oral, investigational combination for chronic hepatitis B virus (HBV) infection. **JNJ-56136379** is a *hepatitis B virus capsid assembly modulator* that interferes with the formation of functional viral capsids, inhibiting HBV replication. **Entecavir** is a *nucleoside analogue* that inhibits HBV DNA polymerase, decreasing viral DNA synthesis. The combination aims to suppress HBV replication through dual mechanisms, and is under clinical investigation for use in patients with chronic hepatitis B, including those with or without prior nucleos(t)ide analogue treatment[1][3][5][2][4][6].

Other names: entecavir

Targets

HBV Pol (Hepatitis B virus polymerase)UGT2B7 (UDP-glucuronosyltransferase 2B7)CYP3A4 (Cytochrome P450 3A4)UGT1A1 (UDP-glucuronosyltransferase 1A1)HBc (Hepatitis B virus core protein)

Beyond the preview

Go deeper on JNJ-56136379 + entecavir.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JNJ-56136379 + entecavir.

Explore the full profile